Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet RNA Biomarkers to Tailor Antiplatelet Therapy
NCT05278637Phase 1Completed
- Sponsor
- Duke University
- Start
- Nov 2013
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aspirin and ticagrelor in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Duke University. Primary endpoint: Change in expression levels of platelet messenger RNA at 4 weeks. Started Nov 2013; status: completed.
02
Drugs
aspirinticagrelor
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05278637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278637.